Thomas C. Waddington

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase II Trial of Lung Chemoembolization”.

Phase II Trial of Lung Chemoembolization

Journal of Vascular and Interventional Radiology(2023)10.1016/j.jvir.2023.08.006

N/A

0.201DataRank · unranked

2 citations

Ravi Salgia, Thomas C. Waddington, Erminia Massarelli, John J. Park, Jonathan Kessler +4 more

Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.009

N/A

0DataRank · unranked

7 citations

Isa Mambetsariev, Rebecca Pharaon, Jeremy Fricke, Angel Ray Baroz, Hannah Romo +4 more

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps2665

N/A

0DataRank · unranked

4 citations

Stephen J. Forman, Joycelynne Palmer, Timothy W. Synold, Lei Tian, Ting Lu +14 more